Clinical Trial: NRG CCTG MA.39

NRG CCTG MA.39

Status: Open

Tailor RT: A Randomized Trial of Regional Radiotherapy in Biomarker Low Risk Node Positive and T3N0 Breast Cancer

Eligible for screening study DCP 001

For CCTG MA.39, please credit NRG all accruals.

CCTG MA.39-Optional Questionnaire Component is closed to accrual effective August 2, 2022